Physician profile
Dev R Rellan
NPI 1760421648
$4,312.65
in general payments reported to CMS, 2019-2025
27 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,671 · 2020: $709 · 2021: $307 · 2022: $151 · 2023: $65.24 · 2024: $181 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $475.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $941.52 | 2019-2025 | |
| Novo Nordisk INC | $543.85 | 2019-2021 | |
| Vifor Pharma, INC. | $420.54 | 2019-2022 | |
| Amgen INC. | $382.36 | 2019-2020 | |
| Amarin Pharma, INC. | $371.55 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $308.17 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.56 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $246.57 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.46 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $135.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $82.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $68.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.45 | 2019 | |
| Shire North American Group INC | $29.34 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $28.76 | 2019 | |
| Janssen Biotech, INC. | $24.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.11 | 2021 | |
| Genentech USA, INC. | $16.41 | 2020 | |
| Portola Pharmaceuticals, LLC | $16.14 | 2019 | |
| Horizon Therapeutics Plc | $15.50 | 2022 | |
| Ironwood Pharmaceuticals, INC | $14.24 | 2019 | |
| Optinose US, INC. | $13.37 | 2019 | |
| Allergan, INC. | $11.50 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.46 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dev Rellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.